Emerging multiple sclerosis oral therapies.

Emerging oral therapies for Multiple Sclerosis. Report of the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

Emerging oral disease-modifying therapies

Over the last two decades, patients have relied on the use of self-injectable disease modifying agents for the treatment of multiple sclerosis. The need for frequent injections has affected treatment up take and adherence. Fingolimod, the first oral disease modifying agent to be licensed in Europe and the United States, has been shown to be effective in reducing relapse rates in comparison to p...

Novel Agents and Emerging Treatment Strategies in Multiple Sclerosis

In the past decade, the treatment of multiple sclerosis has undergone a significant paradigm shift. Weekly to daily self-injections of moderate benefit are making way for more effective therapies with improved relapse and disability impact with more appealing routes and frequencies of administration. Some such therapies, like natalizumab, belong to the monoclonal antibody family, while others o...

Emerging Therapies of Multiple Sclerosis

5. Monoclonal Anti body Multi ple sclerosis (MS) is a complex immunopathologic disorder of the central nervous system (CNS). For the past several years, there have been six agents approved by regulatory agencies to treat relapsing forms of multi ple sclerosis (MS): interferon beta-1b, intramuscular interferon beta-1a, subcutaneous interferon beta-1a, glati ramer acetate, natalizumab, and mitoxa...

Clinical trials in pediatric multiple sclerosis: overcoming the challenges

To date, none of the formative clinical drug trials in multiple sclerosis (MS) have included children. Just as in other fields in pediatrics, current prescribed therapies are off-label and are based on the results of adult studies. Emerging oral, injectable and intravenous immunotherapies appear to be more efficacious, but simultaneously have more worrisome side effects. In order to optimize th...

New oral disease-modifying therapies for multiple sclerosis

Several promising, oral disease-modifying therapies for multiple sclerosis are currently being evaluated in clinical trials. The arrival of effective oral agents for multiple sclerosis will be a major advance in the global effort to alter the natural history of this chronic disease.